Department of Neurosurgery, University of Kansas Medical Center, Kansas City, Kansas.
Indiana Spine Group, Carmel, Indiana.
Neurosurgery. 2018 Sep 1;83(3):377-384. doi: 10.1093/neuros/nyx432.
i-Factor™ Bone Graft (Cerapedics Inc, Westminster, Colorado) is a composite bone substitute material consisting of P-15 synthetic collagen fragment adsorbed onto anorganic bone mineral suspended in an inert biocompatible hydrogel carrier. A pivotal, noninferiority, US FDA Investigational Device Exemption study demonstrated the benefits of i-Factor™ compared to local autograft bone in single-level anterior cervical discectomy and fusion at 1-yr postoperative.
To report 2-yr follow-up.
Subjects randomly received either autograft (n = 154) or i-Factor™ (n = 165) in a cortical ring allograft and followed using radiological, clinical, and patient-reported outcomes.
At 2 yr, the fusion rate was 97.30% and 94.44% in i-Factor™ and autograft subjects, respectively (P = .2513), and neurological success rate was 94.87% (i-Factor™) and 93.79% (autograft; P = .7869). Neck Disability Index improved 28.30 (i-Factor™) and 26.95 (autograft; P = .1448); Visual Analog Scale arm pain improved 5.43 (i-Factor™) and 4.97 (autograft) (p = .2763); Visual Analog Scale neck pain improved 4.78 (i-Factor™) and 4.41 (autograft; P = .1652), Short Form-36 (SF-36v2) Physical Component Score improved 10.23 (i-Factor™) and 10.18 (autograft; P = .4507), and SF36v2 Mental Component Score improved 7.88 (i-FactorTM) and 7.53 (autograft; P = .9872). The composite endpoint of overall success (fusion, Neck Disability Index improvement >15, neurological success, and absence of re-operations) was greater in i-Factor™ subjects compared to autograft subjects (69.83% and 56.35%, respectively, P = .0302). Twelve (7.45%) i-Factor™ subjects and 16 (10.53%) autograft subjects underwent re-operation (P = .3411). There were no allergic reactions associated with i-Factor™.
Use of i-Factor™ in anterior cervical discectomy and fusion is effective and safe, and results in similar outcomes compared to local autograft bone at 2 yr following surgery.
i-FactorTM 骨移植物(Cerapedics Inc,科罗拉多州威斯敏斯特)是一种复合骨替代材料,由 P-15 合成胶原片段吸附在无机组分的骨矿物质上,悬浮在惰性生物相容性水凝胶载体中。一项关键性的、非劣效性的美国食品和药物管理局调查设备豁免研究表明,与单节段前路颈椎间盘切除融合术的局部自体骨相比,i-FactorTM 在术后 1 年具有优势。
报告 2 年的随访结果。
受试者随机接受皮质环同种异体移植物中的自体骨(n = 154)或 i-FactorTM(n = 165)治疗,并采用影像学、临床和患者报告的结果进行随访。
在 2 年时,i-FactorTM 和自体骨组的融合率分别为 97.30%和 94.44%(P =.2513),神经功能成功的比例分别为 94.87%(i-FactorTM)和 93.79%(自体骨;P =.7869)。颈部残疾指数改善 28.30(i-FactorTM)和 26.95(自体骨;P =.1448);视觉模拟量表手臂疼痛改善 5.43(i-FactorTM)和 4.97(自体骨)(p =.2763);视觉模拟量表颈部疼痛改善 4.78(i-FactorTM)和 4.41(自体骨;P =.1652),简明健康调查问卷 36 项简表(SF-36v2)生理评分改善 10.23(i-FactorTM)和 10.18(自体骨;P =.4507),SF-36v2 心理评分改善 7.88(i-FactorTM)和 7.53(自体骨;P =.9872)。与自体骨组相比,i-FactorTM 组的总体成功率(融合、颈部残疾指数改善>15、神经功能成功和无再次手术)更高(分别为 69.83%和 56.35%,P =.0302)。12 例(7.45%)i-FactorTM 组和 16 例(10.53%)自体骨组患者接受了再次手术(P =.3411)。与 i-FactorTM 相关的过敏反应为零。
在前路颈椎间盘切除融合术中使用 i-FactorTM 是有效和安全的,与术后 2 年的局部自体骨相比,结果相似。